Wednesday, 24 June 2026
Blood pressure reduction impacts, Tenecteplase trial for stroke, Bariatric surgery decline trends
- 01
Study Reveals Impact of Blood Pressure Reduction in Hypertension
A network meta-analysis involving 144,220 individuals with hypertension indicates that lowering systolic blood pressure by 10, 20, or 30 mm Hg can significantly reduce cardiovascular disease events by 29%, 42%, and 54%, respectively. Hypertension affects approximately 1.4 billion people globally, with a high prevalence among those aged 40 to 59 years and those aged 60 years and older. The findings underscore the importance of effective blood pressure management, as most individuals with hypertension require multiple antihypertensive medications to achieve control.
via JAMA
- 02
OPTION Trial Evaluates Tenecteplase for Ischemic Stroke
The OPTION trial assessed the use of intravenous tenecteplase for patients with acute non-large vessel occlusion ischemic stroke, administered between 4.5 and 24 hours post-onset. Patients were selected based on CT perfusion imaging. While the study addresses significant aspects of acute stroke care, the findings require careful interpretation due to safety considerations and the clinical context.
via JAMA
- 03
Decrease in Bariatric Surgeries Linked to Rise in GLP-1 Drug Use
A research letter in JAMA Surgery reports a decline in metabolic bariatric surgeries coinciding with the increased popularity of glucagon-like peptide-1 (GLP-1) medications. This trend indicates a shift in obesity management strategies. The findings may influence prescribing practices among Australian GPs as they navigate treatment options for obesity.
via JAMA
- 04
Analysis of US Adult Obesity Trends and Forecasts
A recent analysis published in JAMA examined obesity prevalence in the US from 1990 to 2022, with forecasts extending to 2035. The study utilised modeling techniques from the Global Burden of Disease project, which are known for providing reliable disease burden estimates. The authors caution that the forecasts depend on the continuation of pre-2022 trends, without considering potential disruptions, such as the increasing use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). This analysis offers insights into obesity trends that may inform public health initiatives.
via JAMA
- 05
Challenges in Containing Current Ebola Outbreak in DRC
The ongoing Ebola outbreak in the Democratic Republic of the Congo poses significant public health challenges, particularly regarding the Bundibugyo virus, which lacks a vaccine or specific treatment. The situation raises concerns about containment efforts and the potential for wider implications. This outbreak highlights the complexities of managing rare viral infections in affected regions.
via JAMA
- 06
US Drug Overdose Deaths Decline for Third Year
The US Centers for Disease Control and Prevention (CDC) reported a decrease in drug overdose deaths in 2025, marking the third consecutive year of decline. This trend may provide insights into substance use patterns and treatment approaches relevant to clinicians. The ongoing reduction in overdose fatalities highlights a significant shift in public health outcomes.
via JAMA
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.